Nordion

Nordion Named One of National Capital Region's Top 25 Employers for Sixth Consecutive Year

Tue, 07 Feb 2012 09:00:00 EST

Nordion Inc., a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease, has been named one of the National Capital Region's Top 25 Employers by Mediacorp Canada, the nation's largest publisher of employment-related periodicals and online directories. This is the sixth consecutive year Nordion has received this recognition.

Nordion Announces the Renewal of its Normal Course Issuer Bid

Tue, 31 Jan 2012 11:30:00 EST

Nordion Inc., a leading provider of products and services to the global health sciences market, today announced that its Board of Directors has approved the renewal of its Normal Course Issuer Bid (NCIB) to purchase for cancellation common shares of the Company through the facilities of the Toronto Stock Exchange (TSX) and the New York Stock Exchange (NYSE), or other alternative trading systems, if eligible.

Nordion CEO Steve West Shares Personal Cancer Story

Fri, 20 Jan 2012 15:30:00 EST

In September 2011, just after completing the Ride the Rideau bike event, Nordion CEO Steve West was diagnosed with non-Hodgkin's Lymphoma. Coincidentally, his treatment at The Ottawa Hospital Cancer Centre included participation in a clinical trial, which was the fundraising focus of the Ride for 2011. Steve credits his busy work and sports training regimen, which included cycling in Ride the Rideau, for getting him through his cancer diagnosis and treatment...

Nordion Enters Six-Year Cobalt-60 Supply Agreement with Synergy Health

Thu, 19 Jan 2012 08:00:00 EST

Nordion Inc., a leading provider of products and services to the global health sciences market, of products and services to the global health science market, announced today it has signed a six-year contract to supply cobalt-60 to Synergy Health, a leading international contract sterilization service company headquartered in the United Kingdom. Under the terms of the agreement, the contract extends until October 31, 2017.

Nordion Reports Strong Fiscal 2011 Financial Results; Provides Fiscal 2012 Outlook

Tue, 13 Dec 2011 19:40:00 EST

Nordion Inc., a leading provider of products and services to the global health sciences market, today reported fourth quarter revenues of $74.0 million, down $7.6 million compared with $81.6 million in the fourth quarter of fiscal 2010. For fiscal 2011, revenues increased 23% to $274.0 million from revenue of $222.0 million in fiscal 2010.

Nordion Inc. Declares Quarterly Dividend

Tue, 13 Dec 2011 19:40:00 EST

The Board of Directors for Nordion Inc., a leading provider of products and services to the global health science market, today declared a quarterly dividend of US$0.10 per share on the outstanding common shares of the Company. The dividend is payable on January 3, 2012 to shareholders of record at the close of business on December 23, 2011.

Nordion 2011 Annual Report

Tue, 13 Dec 2011 19:40:00 EST

Passion. Performance. Growth. Look inside...

Nordion to Release Fourth Quarter and Fiscal 2011 Financial Results

Tue, 06 Dec 2011 08:00:00 EST

Nordion Inc., a leading provider of products and services to the global health science market, today announced that the Company will report its fourth quarter and Fiscal 2011 financial results after market close on December 13, 2011.

NordionInc is Now on Twitter

Mon, 21 Nov 2011 11:00:00 EST

Follow Nordion on Twitter: @NordionInc

Nordion Issues Statement Upon Chalk River Operating Licence Renewal

Thu, 27 Oct 2011 17:00:00 EST

Nordion is pleased to hear that the Canadian Nuclear Safety Commission (CNSC) has renewed the Operating Licence for Atomic Energy Canada Limited’s (AECL) Chalk River Laboratories to October 31, 2016...

Nordion Provides Updated Schedule for MAPLE Arbitration

Fri, 21 Oct 2011 08:00:00 EST

Nordion Inc., a leading provider of products and services to the global health science market, today released an update to the schedule for the ongoing arbitration with Atomic Energy of Canada Limited (AECL) relating to the MAPLES, the nuclear reactors that were being commissioned to serve as the Company's source of long-term medical isotope supply.

Nordion Featured on BioTuesdays.com

Tue, 11 Oct 2011 11:00:00 EST

Nordion, the last man standing after the breakup of the MDS health sciences conglomerate, has its eye on building a bigger portfolio of targeted therapeutics to complement its TheraSphere liver cancer therapy...

Nordion Awards Contract for Phase III Clinical Trials to Theorem Clinical Research

Thu, 16 Jun 2011 07:00:00 EST

Nordion Inc., a leading provider of products and services to the global health science market, today announced that Theorem Clinical Research, previously Omnicare Clinical Research, a full service Contract Research Organization (CRO) has been awarded the contract to conduct Nordion's recently announced TheraSphere Phase III clinical trials for the treatment of primary and metastatic liver cancers - STOP-HCC and EPOCH.